Augtyro

Oman · access guide

How to access Augtyro for ROS1-positive non-small-cell lung cancer and NTRK-positive solid tumours from Oman: 2026 pathway via Oman oncology and regional referral

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Home / Access Guides / Augtyro - Oman
Oman's adult medical oncology services run out of Sultan Qaboos University Hospital (SQUH) (KHUH), Royal Hospital Muscat, and Muscat Private Hospital, with established referral pathways to KFSHRC Riyadh, NCCCR Doha, and the UAE oncology centres for cases requiring deeper subspecialty infrastructure. Paediatric NTRK cases age 12 and older typically refer cross-border to KFSHRC paediatric oncology or to Sidra Medicine via the MoH treatment-abroad pathway. Augtyro (repotrectinib) is a Bristol Myers Squibb next-generation tyrosine kinase inhibitor covering ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults and NTRK gene fusion-positive solid tumours in adults and paediatric patients age 12 years and older. The FDA approved ROS1 in November 2023 and expanded to NTRK fusions in June 2024. The Oman supply route in 2026 most commonly runs through the named-patient programme (NPP) pathway via the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC).

This page explains how the pathway works in 2026 for a Oman-resident patient: who qualifies, where the diagnostic and molecular workup happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in OMR, what to monitor on therapy, and how the multi-year treatment course settles into a Omani family's life.

Why Augtyro, and why now

Augtyro is repotrectinib (TPX-0005), discovered at Turning Point Therapeutics, acquired by Bristol Myers Squibb in August 2022. FDA approved November 2023 for ROS1-positive locally advanced or metastatic NSCLC in adults (TRIDENT-1, ORR 79 percent TKI-naive, intracranial ORR 89 percent). Expanded June 2024 to NTRK gene fusion-positive solid tumours in adults and paediatric patients age 12 and older (TRIDENT-1 NTRK cohort, ORR 58 percent TKI-naive).

For a Omani patient with confirmed ROS1-positive NSCLC or NTRK-positive solid tumour, Augtyro is the named-patient route for first-line or post-first-generation-TKI treatment under most institutional protocols followed by KHUH, Royal Hospital Muscat, and Muscat Private Hospital. The eligibility gatekeeper is biomarker confirmation.

What Augtyro is, in plain language

Augtyro is an oral capsule. 160 mg once daily for 14 days (lead-in), then 160 mg twice daily (maintenance), with food. Room temperature storage. No infusion, no inpatient stay, no certified-centre requirement.

The 14-day lead-in is about managing initial dizziness. Driver support during the first two weeks is part of the practical handoff.

For metastatic disease, treatment continues until progression or intolerable

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com